Zosano Pharma Corp (ZSAN) Given Consensus Rating of “Strong Buy” by Analysts

Shares of Zosano Pharma Corp (NASDAQ:ZSAN) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Brokers have set a twelve-month consensus price target of $19.00 for the company, according to Zacks. Zacks has also given Zosano Pharma an industry rank of 101 out of 255 based on the ratings given to its competitors.

A number of analysts have weighed in on ZSAN shares. ValuEngine upgraded Zosano Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. BTIG Research started coverage on Zosano Pharma in a research note on Thursday, June 28th. They issued a “buy” rating on the stock.

ZSAN traded down $0.16 during trading on Tuesday, reaching $4.16. The company had a trading volume of 369,290 shares, compared to its average volume of 325,844. Zosano Pharma has a 52 week low of $3.61 and a 52 week high of $25.80.

Zosano Pharma (NASDAQ:ZSAN) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.14.

Hedge funds have recently added to or reduced their stakes in the business. Neuburgh Advisers LLC purchased a new stake in Zosano Pharma in the first quarter worth $133,000. BlackRock Inc. increased its stake in Zosano Pharma by 481.7% in the second quarter. BlackRock Inc. now owns 27,549 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 22,813 shares during the period. CIBC Private Wealth Group LLC purchased a new stake in Zosano Pharma in the second quarter worth $131,000. Tyers Asset Management LLC purchased a new stake in Zosano Pharma in the first quarter worth $169,000. Finally, Flinton Capital Management LLC purchased a new stake in Zosano Pharma in the first quarter worth $206,000. Institutional investors and hedge funds own 47.34% of the company’s stock.

Zosano Pharma Company Profile

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.

Featured Article: Are analyst ratings accurate?

Get a free copy of the Zacks research report on Zosano Pharma (ZSAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply